Clinical Trials
34
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials
A Trial Comparing the Pharmacodynamics and Pharmacokinetics of BC Combo THDB0207 and Lantus® and Humalog® in Subjects With Type 1 Diabetes
- Conditions
- Type 1 Diabetes
- Interventions
- Drug: Euglycemic clamp with BC Combo THDB0207Drug: Euglycemic clamp with Humalog®Drug: Euglycemic clamp with Lantus®
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Adocia
- Target Recruit Count
- 30
- Registration Number
- NCT05373199
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneous Injections of Humalog® and Lantus® in Healthy Chinese Volunteers
- Conditions
- Healthy
- Interventions
- Drug: Euglycemic clamp with BC Combo THDB0207Drug: Euglycemic clamp with Humalog® Mix25Drug: Euglycemic clamp with Humalog® and Lantus®
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Adocia
- Target Recruit Count
- 27
- Registration Number
- NCT05373186
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
A Trial Investigating the Dose Linearity and Safety of BC Combo THDB0207 in Subjects With Type 2 Diabetes
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: Euglycemic clamp with BC Combo THDB0207Drug: Euglycemic clamp with Humalog® Mix25
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Adocia
- Target Recruit Count
- 40
- Registration Number
- NCT05373212
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
A Trial to Assess the Efficacy and Safety of M1 Pram P037 Prandial Insulin in Subjects With Type 1 Diabetes (T1DM)
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Drug: M1 Pram P037
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2022-06-24
- Lead Sponsor
- Adocia
- Target Recruit Count
- 80
- Registration Number
- NCT04816890
- Locations
- 🇩🇪
Profil Mainz GmbH & Co, Mainz, Germany
🇩🇪Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus
- Conditions
- Type 1 Diabetes
- Interventions
- Drug: Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1)Drug: Administration of Ready-to-use BioChaperone insulin lispro (IMP2)Drug: Administration of US-approved Humalog® (IMP3)Drug: Administration of EU-approved Humalog® (IMP4)
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Adocia
- Target Recruit Count
- 32
- Registration Number
- NCT04501107
- Locations
- 🇩🇪
Profil GmbH, Mainz, Germany
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
Adocia's Ultra-Rapid Insulin BioChaperone Lispro Meets Primary Endpoint in Phase 3 Trial for Type 2 Diabetes
BioChaperone Lispro (THDB0206) demonstrated non-inferior HbA1c reduction compared to Humalog in a Phase 3 trial of 1,040 Chinese adults with Type 2 diabetes.
Adocia Secures €9.7 Million Private Placement to Advance Diabetes and Obesity Pipeline Through Q2 2026
Adocia successfully completed a €9.7 million private placement through issuing 2.125 million new shares with attached warrants, extending the company's cash runway to Q2 2026.
Monthly Semaglutide Injection Shows Promise in Early Trials
A novel hydrogel formulation of semaglutide allows for a slow, steady release of the drug over one month, potentially reducing the frequency of injections.